In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Shares of Eli Lilly (LLY) fell in premarket trading Thursday after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that came in above analysts' expectations ...

Price Targets: Delving into movements, analysts provide estimates for the future value of Eli Lilly and Co's stock. This analysis reveals shifts in analysts' expectations over time.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Overall, Eli Lilly posted a solid Q2 and that also reflects in its stock price move. However, we think it’s appropriately valued at levels of over $900.

Shares of Eli Lilly are up more than 130% in the past year, but this company's moves are far from finished.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly's Q3 results show strong sales growth, especially in its Mounjaro and Zepbound franchises, but lowered 2024 outlook leads to investor concerns. Read more here.

3. Justifying its valuation with its outlook Eli Lilly's valuation might be a significant stumbling block for some investors. If the stock fails to meet the market's lofty expectations, its shares ...

Eli Lilly (LLY 0.40%) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival.

Financial Milestones: Eli Lilly's Journey Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers.